Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Ashina, Messoud ; Amin, Faisal Mohammad ; Kokturk, Pinar ; Cohen, Joshua M ; Konings, Martijn ; Tassorelli, Cristina ; Lyras, Leonidas ; Mitsikostas, Dimos-Dimitrios. / PEARL study protocol : a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. In: Pain Management. 2021 ; Vol. 11, No. 6. pp. 647-654.

Bibtex

@article{8d6ea45a646648fcb0f9ec5000a861cd,
title = "PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine",
abstract = "Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.",
keywords = "adherence, calcitonin gene-related peptide, chronic, episodic, fremanezumab, migraine, persistence, real world",
author = "Messoud Ashina and Amin, {Faisal Mohammad} and Pinar Kokturk and Cohen, {Joshua M} and Martijn Konings and Cristina Tassorelli and Leonidas Lyras and Dimos-Dimitrios Mitsikostas",
year = "2021",
month = nov,
doi = "10.2217/pmt-2021-0015",
language = "English",
volume = "11",
pages = "647--654",
journal = "Pain Management",
issn = "1758-1869",
publisher = "Future Medicine Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - PEARL study protocol

T2 - a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

AU - Ashina, Messoud

AU - Amin, Faisal Mohammad

AU - Kokturk, Pinar

AU - Cohen, Joshua M

AU - Konings, Martijn

AU - Tassorelli, Cristina

AU - Lyras, Leonidas

AU - Mitsikostas, Dimos-Dimitrios

PY - 2021/11

Y1 - 2021/11

N2 - Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.

AB - Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.

KW - adherence

KW - calcitonin gene-related peptide

KW - chronic

KW - episodic

KW - fremanezumab

KW - migraine

KW - persistence

KW - real world

UR - http://www.scopus.com/inward/record.url?scp=85115661814&partnerID=8YFLogxK

U2 - 10.2217/pmt-2021-0015

DO - 10.2217/pmt-2021-0015

M3 - Journal article

C2 - 34105377

VL - 11

SP - 647

EP - 654

JO - Pain Management

JF - Pain Management

SN - 1758-1869

IS - 6

ER -

ID: 66500888